Becker's Healthcare November 14, 2024
A six-month shortage of cisplatin, a drug used in the treatment of head and neck cancer, resulted in a 16% total cost increase for practices in the U.S. Oncology Network, according to a study presented Sept. 27-28, at the American Society of Clinical Oncology’s 2024 Quality Care Symposium in San Francisco.
Researchers from 26 practices in The Woodlands, Texas-based U.S. Oncology Network analyzed drug administration data for the six-month periods before, during and after the cisplatin shortage, according to a Nov. 10 news release from The ASCO Post.
The cisplatin shortage began in February 2023. Though the FDA declared an official end to the shortage June 28, 2024, the study defined the shortage period from February 2023 to August...
Today's Sponsors
Today's Sponsor